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Background: Popliteal artery stenting is not routinely performed due to concerns related to the high mobility of the knee
joint and the potential for external stent compression, fractures, and occlusion. Open bypass is traditionally considered
the gold standard for popliteal artery atherosclerotic lesions. The Supera stent (IDEV Technologies Inc, Webster, Tex)
was developed to provide superior radial strength, fracture resistance, and ﬂexibility compared with laser-cut nitinol
stents. This study represents the initial United States experience in the management of popliteal artery atherosclerotic
disease with the Supera interwoven wire stent.
Methods: Patients undergoing stent implantation in the 20-month period after the 2008 Food and Drug Administration
clearance were included. Medical records, radiographic imaging, and procedural data were examined. Procedural
angiograms were classiﬁed according to Trans-Atlantic Inter-Society Consensus criteria. Patency and limb loss rates were
calculated using Kaplan-Meier analysis.
Results: A total of 39 stents were placed in 34 patients due to isolated popliteal artery occlusive disease. Clinical follow-up
was a mean of 12.7 months (range, 0.2-33.7 months), and radiologic follow-up was a mean of 8.4 months (range,
0-26.8 months). Most patients had critical limb ischemia (CLI), with tissue loss (38.2%) or rest pain (35.3%) as the
indication for intervention. In 20 patients (58.8%), the most distal end of the stent(s) landed in the below-the-knee
popliteal segment, 12 (35.3%) landed in the above-the-knee segment, and two (5.9%) landed precisely at the knee.
Other than angioplasty and stenting, 47% of patients did not receive any adjuvant concomitant therapy in the treated leg.
Two patients underwent concomitant atherectomy of the popliteal segment. Primary, primary assisted, and secondary
patency rates by duplex ultrasound imaging were 79.2%, 88.1% and 93%, respectively, by Kaplan-Meier estimates, with
a mean stented length of 12 cm. Six instances of stent occlusion were noted, and six patients were identiﬁed with
hemodynamically signiﬁcant in-stent stenosis. Three patients sustained limb loss (8.8%), two related to uncontrolled
infections, and one due to perioperative ischemic complications (both with patent stents at the time of limb loss). The
overall mortality was 8.8% during the study period. Knee roentgenography was performed in all but one patient, and no
stent fractures were identiﬁed.
Conclusions: Stenting of the popliteal artery using the Supera stent system appears to be safe and effective. The interwoven
stent design may better serve areas under extreme mechanical stress. Our results with this highly diseased patient
population justify a prospective trial in this subject. (J Vasc Surg 2013;57:1014-22.)Lower extremity revascularization with endoluminal
techniques requiring stenting was previously limited to
occlusive disease in areas with limited repetitive motion,
external compression, and in segments proximal or distal
to the hip and knee joints. The mobility of the knee joint
results in complex forces that have been associated with
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4generally considered the treatment of choice for lesions
involving the popliteal artery behind the knee. A novel
woven nitinol wire form with high radial expansion
strength and longitudinal ﬂexibility has been developed
and has shown an increased resistance to compression,
kinking, and fracture compared with laser-cut self-expand-
ing nitinol stents in in vitro testing.
The Supera (IDEV Technologies Inc, Webster, Tex)
self-expanding, nitinol stent, transhepatic biliary system
received United States (U.S.) Food and Drug Administra-
tion (FDA) 510(k) clearance for palliative treatment of
biliary strictures produced by neoplasms in 2008. In
Europe, the Supera stent has received the Conformité
Européene (CE) mark approval for biliary and peripheral
vascular indications, and the 24-month results for treat-
ment of lesions of the superﬁcial femoral artery (SFA)
have been recently reported.1 The purpose of this study
is to evaluate the clinical outcomes with the use of the
Supera stent in the management of popliteal artery athero-
sclerotic lesions in a severely diseased patient population.
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ing of the popliteal artery using the Supera system.
METHODS
Institutional Review Board approval from Tucson
Medical Center was obtained in March 2009. Consecutive
patients undergoing popliteal artery stenting in the
20-month period after the January 2008 FDA clearance
were included, based on a prospectively maintained data-
base of endovascular procedures performed at Tucson
Medical Center. The study excluded patients who under-
went stent placement as an extension for the treatment of
SFA occlusive disease. Inpatient and outpatient medical
records, radiographic imaging, and procedural data were
examined and recorded. Demographic features were ex-
tracted, including age, race, sex, and risk factors, including
diabetes, hypertension, coronary artery disease, chronic
obstructive pulmonary disease, active smoking or a history
of tobacco use, hyperlipidemia, chronic anticoagulation,
renal dysfunction, and evidence of peripheral arterial
disease elsewhere in the body. The American Society of
Anesthesiologists (ASA) Physical Status classiﬁcation was
used for each patient.
Preprocedural and postprocedural creatinine and
ankle-brachial indexes (ABIs) were recorded. Procedural
characteristics were also recorded, including laterality,
duration of intervention, ﬂuoroscopy time, and iodinated
contrast volume. The procedural angiograms were used
to classify the popliteal lesions according to:
d Trans-Atlantic Inter-Society Consensus (TASC) criteria
I (2000) and II (2007);
d type: stenosis, occlusion, embolic, defects after SFA
remote endarterectomy, stenting of the arterial
segment between the distal aspect of a previously per-
formed femoropopliteal bypass and a severely diseased
popliteal artery;
d length, and
d location above the knee, below the knee, or precisely at
the knee.
All patients underwent a physical examination, duplex
ultrasound imaging, and radiographic imaging during the
clinical follow-up period. Signiﬁcant restenosis was deﬁned
as >50% based on ultrasound-derived velocity parameters
(peak systolic velocity ratio $2.0). Primary patency, cumu-
lative primary assisted patency, secondary patency, resteno-
sis, complication, and limb salvage rates were calculated,
based on duplex ultrasound imaging, for all patients, and
adding ﬁndings from angiography when available. Primary
patency was deﬁned as uninterrupted popliteal stent patency
after the revascularization procedure. Assisted primary
patency expressed patients who underwent a revision of
the revascularization to prevent impending occlusion or
progression of stenosis. Secondary patency referred to
patency of the popliteal stent after a reintervention to restore
patency after occlusion. Knee roentgenography was per-
formed to assess stent integrity. One radiologist and onevascular interventionalist reviewed images independently.
Renal dysfunction was deﬁned as any elevation of creatinine
levels (>1.2 mg/dL) at any point before or after stenting
procedure. Chronic renal insufﬁciency was deﬁned as renal
dysfunction without the need for dialysis.
Statistical analysis. Demographics and safety and efﬁ-
cacy data were summarized using descriptive statistics
according to the data type. Rates were computed for quali-
tative variables, and mean and standard deviation or median
and range are presented for quantitative variables.
The Kaplan-Meier method was used to compute time-
to-event rates. The log-rank test assessed the potential
effect of risk factors on outcome or complications in the
univariate setting.
A multivariate model of the Cox-regression analyzed
the effect of potential risk factors and their interactions.
A value of P # .05 was assumed to show signiﬁcance. All
statistical analyses were performed using SAS 9.2 software
(SAS Institute, Cary, NC).
RESULTS
We identiﬁed from the database 90 consecutive
patients who underwent Supera stent placement across
the knee in the popliteal artery between February 2008
and December 2010. Stents were placed in 34 of 90
patients due to isolated popliteal arterial occlusive disease,
and this subgroup forms the basis for the present report.
All procedures were performed by ﬁve vascular interven-
tionalists at the same institution in a dedicated hybrid suite,
except one was performed in a cardiac catheterization
laboratory.
Demographic features. Patients were a mean age of
75 years (range, 56-93 years), with equal distribution by
sex. By race, 89% were Caucasian, 9% were African Amer-
ican, and 3% were Hispanic. Lesions were right-sided in
65%. The demographic characteristics of our cohort are
reported in Table I, and risk factors and comorbidities are
reported in Table II. Most patients were classiﬁed as ASA
class 3, indicating “patients with severe systemic disease.”
Indications for intervention. Ischemic tissue loss was
the most common indication for intervention (38.2%); 35%
had ischemic rest pain, and nearly 25% had claudication.
One patient (3.1%) presented with embolic occlusion.
According to the Rutherford classiﬁcation, about three-
quarters of these patients were classiﬁed as 4 through 6
(CLI; Table III).
Popliteal lesion characteristics. By TASC criteria, 15
patients were classiﬁed as having TASC D lesions, 13 were
TASC C, ﬁve were TASC B, and one was TASC A. Stents
were placed to treat native popliteal artery occlusions in 15
(44.1%) and popliteal stenoses in 14 (41.2%). Two stents
were placed to treat residual popliteal defects after the
use of an SFA EndoRE Remote Endarterectomy Device
(LeMaitre Vascular Inc, Burlington, Mass), one was placed
to treat in-stent restenosis, and two were used to stent the
segment from the distal anastomosis of a previously placed
femoropopliteal bypass graft into a severely diseased
popliteal artery (Table III). In 18 patients (56.3%), the
Table I. Preoperative characteristics
Parameter
No. (%)
(N ¼ 34) Median Mean Range
Age, years 75.5 75 56-93
Stent length, mm 119 40-240
Ankle-brachial index
Before 0.6 0.7 0-1.5
After 1.1 1 0-1.7
Sex
Male 17 (50)
Female 17 (50)
Race
White 30 (88.2)
Hispanic 1 (2.9)
Black 3 (8.8)
Side
Right 22 (64.7)
Left 12 (36.3)
Indication
Claudication 9 (26.5)
Rest pain 11 (32.4)
Tissue loss 13 (38.2)
Embolic 1 (2.9)
Table II. Risk factors
Variable No. (%) (N ¼ 34)
Diabetes 19 (55.9)
Hypertension 34 (100)
Active tobacco use 5 (14.7)
History of tobacco use 26 (76.5)
Chronic obstructive pulmonary disease 9 (26.5)
Hyperlipidemia 26 (76.5)
Coronary artery disease 23 (67.7)
Peripheral artery disease 30 (88.2)
Prior revascularization 10 (29.4)
Prior anticoagulation or antiplatelet Rx
None 15 (44.1)
Antiplatelet medication 10 (29.4)
Warfarin 9 (26.5)
Chronic renal insufﬁciency 7 (20.6)
Table III. Intraprocedural characteristics-1
Variable No. (%) (N ¼ 34)
Lesion
Stenosis 14 (41.2)
Occlusion 15 (44.1)
Restenosis 1 (2.9)
Remote endarterectomy 2 (5.9)
Bypass 2 (5.9)
Location
Above knee 12 (35.3)
At knee 2 (5.9)
Below knee 20 (58.8)
Vessel runoff, No.
0 3 (9.1)
1 9 (27.3)
2 9 (27.3)
3 12 (36.4)
TASC
A 1 (2.9)
B 5 (14.7)
C 13 (38.2)
D 15 (44.1)
Fontaine classiﬁcation
1 9 (26.5)
2 12 (35.3)
3 13 (38.2)
Rutherford classiﬁcation
3 9 (26.5)
4 12 (35.3)
5 8 (23.5)
6 5 (14.7)
ASA classiﬁcation
2 2 (6.1)
3 29 (87.9)
4 2 (6.1)
ASA, American Society of Anesthesiologists; TASC, Trans-Atlantic Inter-
Society Consensus.
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40-240 mm; Table I).
Stent and delivery system speciﬁcations. Thirty-nine
stents were used in these 34 patients because ﬁve patients
required placement of two stents to encompass the extent
of popliteal artery disease. The stent delivery system went
through a series of modiﬁcations during the course of the
project, but there were no changes to the stent. Stents in
29 cases were of the Generation 2 system; four were of
Generation 1.5, and one was of the earliest generation
(Generation 1). Six stents were 6 mm in diameter, 15
were 5 mm, and 13 were 4 mm (Table IV). The most
distal end of the stent(s) landed in the below-the-knee
segment of the popliteal artery in 20 patients (58.8%), in
the above-the-knee segment in 12 (35.3%), and precisely at
the knee joint in two (5.9%).Procedural details. Procedures were an average length
of 63:31 minutes (range, 21:01-122:02 minutes). Mean
ﬂuoroscopy time was 16.4 minutes (range, 6.0-47.8
minutes), and the mean iodinated contrast volume was
28.4 mL (range, 0-100 mL). The mean serum creatinine
levels before and after the intervention were 1.15 mg/dL
(range, 0.5-3.2 mg/dL) and 0.98 mg/dL (range
0.6-2.9 mg/dL; Table IV). Other than angioplasty and
stenting, 46.9% of patients did not receive any adjuvant
concomitant therapy in the treated leg. Adjuvant therapies
were used in an identical number at the treated arterial
segment before stenting or at different arteries on the same
leg; these included popliteal artery angioplasty or athe-
rectomy before stenting, angioplasty at a different artery in
the same leg, percutaneous thrombolysis or open throm-
boembolectomy before popliteal stenting, open femoral
endarterectomy proximal to the popliteal stent, or remote
endarterectomy in the ipsilateral SFA. Two patients
underwent atherectomy of the popliteal segment before
angioplasty and stenting.
Follow-up. Clinical follow-up was a mean 12.7 months
(range, 0.2-33.7 months), and duplex and radiographic
imaging follow-up averaged 8.4 months (range, 0-26.8
Table IV. Intraprocedural characteristics-2
Variable
No. (%) or
average (range)
Stents, No.
1 29 (85.3)
2 5 (14.7)
Stent diameter
4 mm 13 (38.2)
5 mm 15 (44.1)
6 mm 6 (17.7)
Delivery system generation
Generation 1 1 (2.9)
Generation 1.5 4 (11.8)
Generation 2 29 (85.3)
Procedure time, minutes 63:31 (21:01-122:02)
Creatinine level, mg/dL
Preprocedure 1.15 (0.5-3.2)
Postprocedure 0.98 (0.6-2.9)
Fluoroscopy time, minutes 16.4 (6-47.8)
Contrast volume, mL 28.4 (0-100)
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before intervention to1 (range,0-1.7) after revascularization.
Stent patency. Primary patency rates and primary assis-
ted patency rates were 79.2% and 88.1%, based on Kaplan-
Meier estimates (Figs 1 and 2). Importantly, the patency
rates remained stable through 24 months. Six stent oc-
clusions were detected and are summarized in Table V.
Secondary patency was achieved in three of the six patients
experiencing stent occlusion. No further interventional
attempts at restoration of patency were initiated in two of
the remaining patients. One of those two patients under-
went successful open surgical revision of a failed bypass
graft, and the other experienced limb loss #48 hours after
presentation with acute limb ischemia. Procedural patency
was not achieved in that patient despite concomitant four-
compartment fasciotomy and thrombolytic infusion.
No statistically signiﬁcant differences were noted when
primary, primary assisted, or secondary patency rates were
studied in relation with age, sex, laterality, race, Rutherford
score, lesion location, TASC classiﬁcation, or number of
runoff vessels. Reinterventions for patients with stent
occlusion resulted in a cumulative secondary patency rate
of 93%.
Stent integrity. Anterior-posterior and lateral knee
roentgenography was performed in 33 of 34 patients
(97.1%). No stent fractures were identiﬁed during a mean
interval to follow-up of 17.3 6 6.2 months. One patient
died before device imaging.
Restenosis. Restenosis developed in six patients
(Fig 3). Two patients were diagnosed with hemodynami-
cally signiﬁcant in-stent restenosis atw7 and 8 months after
the index procedure. They were successfully treated with
laser atherectomy and balloon angioplasty. Unfortunately,
the latter patient was diagnosed with a second instance of in-
stent restenosis, which was again treated with laser athe-
rectomy. He remains asymptomatic and with no evidence of
hemodynamically signiﬁcant recurrence. Three additionalpatients were diagnosed with nonhemodynamically signiﬁ-
cant in-stent restenoses at 4, 5, and 8 months after the index
procedures and remained asymptomatic.
An additional patient was diagnosed with a stenosis
proximal to the popliteal stent w3 months after the index
procedure. She underwent placement of an additional stent
to treat the stenotic area. This patient eventually suffered
limb loss due to extensive deep soft tissue infection, which
required a guillotine below-knee amputation, followed by
a transfemoral amputation, w4 months after the index
procedure.
Limb loss. At the latest follow-up, limb loss had
occurred in three patients for a rate of 8.8%. Two of these
were related to uncontrolled infections, and one was due to
perioperative ischemic complications 1 day after the inter-
vention, as has been previously described.
Morbidity. Complications reported included a patient
with a groin puncture site necrosis that required outpatient
surgical debridement, a patient with severe leg swelling that
was ultimately controlled with diuretics and compression
stockings, a patient with thrombolysis after stent occlusion,
which on follow-up images 24 hours after thrombolytic
therapy showed a popliteal pseudoaneurysm that required
successful placement of a covered stent; and a patient
with early recurrent ischemia requiring emergency four-
compartment fasciotomy and surgical bypass.
Mortality. There were no perioperative deaths. Three
patients died at 25.2, 14.8, and 3.8 months after their
lower extremity revascularization procedure for a total
mortality rate of 8.8% at the latest follow-up (Fig 4).
One octogenarian patient was still alive at the latest follow-
up, with no issues related to the lower extremities but was
in hospice status due to progressive deconditioning and
failure to thrive 26.8 months after the index procedure.
DISCUSSION
Surgical vein bypass remains the standard of care for
severely symptomatic popliteal artery atherosclerotic
lesions. Five-year primary patency and secondary graft
patency cumulative rates of 63% to 75% and 80% to 83%
have been reported, with perioperative mortality between
1% and 3%.2-4 The higher patency rates resulting from
surgical reconstruction require consideration of the
increased procedural and perioperative morbidity and
mortality rates that accompany open interventions under
general anesthesia. Surgical interventions for limb salvage
are also often complicated by prolonged recovery and
multiple subsequent procedures and readmissions.5
Minimally invasive procedures have been increasingly
performed for disease involving the popliteal artery.6
Generally, angioplasty (balloon or cryoplasty)14 or atherec-
tomy (mechanical or laser) are preferred for the manage-
ment of popliteal lesions behind the knee due to the lack
of metallic devices capable of withstanding the complex
forces exerted on this arterial segment.7,8 Unfortunately,
the data on the efﬁcacy of those techniques is limited.
Most reports have grouped results with the management
of femoropopliteal9-12 or infrapopliteal13 disease. The
Fig 1. Kaplan-Meier curve shows primary patency of the implanted device.
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compared with the efﬁcacy of a vein bypass. Growing
expectations await results of potential options that could
offer better long-term results such as drug-eluting balloons
or stents, or both.15,16
The choice of a stent for a particular artery depends on
anatomic considerations of lesion location and degree of
calciﬁcation and stent characteristics, including size, proﬁle,
long-term durability, fracture resistance, and cost. Limita-
tions speciﬁc to stent placement in the popliteal artery
include insufﬁcient radial strength to maintain vessel
patency, stent kinking, and fractures. Stent fracture after
implantation has been associated with a high prevalence
of restenoses and occlusions. As a result, stents are not
generally advocated for atherosclerosis affecting the popli-
teal artery. Soga et al17 identiﬁed a 14% fracture rate among
511 consecutive patients who underwent femoropopliteal
nitinol stenting. Stent fracture (hazard ratio, 1.6; P ¼
.03) and hemodialysis (hazard ratio, 1.7; P ¼ .01) were
negative independent predictors of primary patency after
stenting. Scheinert et al18 performed a systematic x-ray
screening for stent fractures in 93 patients. Fractures
were detected in up to 64 of 261 stents (24.5%) used in
the treatment of femoropopliteal lesions with a mean
length of 15.7 cm. The primary patency rate at 12 months
was signiﬁcantly lower for patients with fractures (41.1%
vs 84.3%; P < .0001). To the best of our knowledge,our results indicating complete freedom from fractures
mirror those of other authors, in that no Supera stent frac-
tures have been reported so far in the popliteal location.
There is a need for stents capable of providing strength
and ﬂexibility, particularly in areas of high mechanical
stress, such as the ﬂexion-extension, compression, and rota-
tional forces exerted in anatomic segments with mobile
joints. Most studies evaluating the patency of stents behind
the knee joint have been in the use of covered wire forms
for the endovascular repair of popliteal artery aneu-
rysms.19-25 Acknowledging the differences between athero-
sclerotic and aneurysmal disease, we believe that these
outcomes are helpful to give an idea of expected patency
rates across a highly mobile joint. Widely variable patency
ranges have been reported. Primary patency rates of 47%
to 93.9% at 12 months and 68% to 98% at 24 months
with the Viabahn stents (W. L. Gore & Associates, Flag-
staff, Ariz) are reported. The secondary patency rates
were between 75% and 100% at 23 months and 96.8%
and 100% at 24 months.19-24 Limb salvage rates of 75%
to 100% at 60 months were reported in a review by Wain
and Hines.25
To the best of our knowledge, the only reported study
with the use of popliteal stents for atherosclerotic disease is
from Switzerland. Kickuth et al26 studied 35 patients with
Rutherford category 3 to 5 disease who underwent nitinol,
self-expanding stenting. These stents were placed only
Table V. Stent occlusion summary
Pt Indication
Time to
occlusion Etiology
Prior
bypass Stented length, mm
Secondary patency
achieved
1 Claudication 3 months Failure of anticoagulation No 180 Yes
2 Tissue loss 4 days Operator error No 240 Yes
3 Rest pain 7 days Operator error No 120 Yes
4 Acute limb ischemia <24 hours Advanced ischemia Yes 80 No
5 Claudication 3 months Poor runoff No 200 No
6 Rest pain 7 months Bypass failure Yes 120 No
Fig 2. Kaplan-Meier curve shows primary assisted patency of the implanted device.
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recoil were noted after angioplasty. Among them, 22
patients underwent distal popliteal stent placement, and
others underwent tibial-peroneal trunk stenting; unfortu-
nately, both cohorts were grouped in their results. The
primary cumulative patency rate at 6 months was 82%,
with a limb salvage rate of 100%.
The Supera stent is a 0.014/0.018-inch guidewire-
compatible, sheath-based delivery system. The safety and
effectiveness for its use in the vascular system have not
yet been established in the U.S. Stent deployment is
accomplished by advancing a ratchet-type mechanism actu-
ated by a thumb slide distally while the stent handle is heldstationary. The wire interwoven nitinol, conﬁgured in
a helical pattern, confers to the stent a superior radial
strength, multidimensional ﬂexibility, durability, and vessel
conformity compared with traditional laser-cut nitinol tube
stents (Fig 5).
Data with the use of this stent in the SFA and popliteal
arteries have been recently reported in Germany. The Leip-
zig SFA registry included data on 107 patients who received
the Supera stent for treatment of femoropopliteal artery
lesions, showing a primary patency of 84.7% at 12 months
without fractures. It is important to point out differences
between our population and the European cohort. First,
the German registry included a high number of patients
Fig 4. Kaplan-Meier curve shows mortality among the cohort.
Fig 3. Kaplan-Meier curve shows secondary patency of the implanted device.
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CLI. Second, most of their stents did not cross the knee
joint (only 3.7% reached the distal third of the artery).
Third, their mortality rate was 5%. In comparison, 20 stents
in our series landed in the distal popliteal artery, for a total
of 58.8% crossing the knee. Our population included
patients with severe comorbidities, with more than twice
the mortality and CLI rates of the Leipzig cohort.The aim of this study was to establish proof of concept
and to determine the efﬁcacy and durability of a new device
deployed in a location typically considered unsuitable for
metallic structural support devices. With this in mind,
inclusion of all patients with stent placement across the
knee joint was felt to be appropriate. For this reason,
patients were analyzed who had previously undergone
bypass surgery and would have been excluded in any other
Fig 5. Supera Woven Nitinol Stent (IDEV Technologies Inc,
Webster, Tex).
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results indicate superior patency rates compared with other
types of interventions performed in the arterial system at
the knee joint and absolute freedom from fracture during
the study period. Removal of the latter subset of patients
from our data set results would result in an increased
primary patency rate of 87.5%.
The limitations to our work include a low number of
patients studied, the retrospective nature of our study,
and a lack of standardization in our procedural methods
and routine follow-up algorithms among the vascular inter-
ventionists involved in this project. Further, the signiﬁcant
increase in the ABI before and after interventions could
have been somewhat inaccurate given the lack of more
hemodynamic parameters of intervention success included
in our analysis, such as toe pressures or waveforms. The
known effect of vascular calciﬁcation in the calculation of
an ABI, especially in diabetic individuals could have given
erroneous measurements in these indexes.
CONCLUSIONS
Popliteal artery stenting with the Supera system is safe
and effective, with high patency rates. The interwoven wire
design appears to better serve areas exposed to extreme
mechanical stress, which is highly important in patients
with chronic CLI, the elderly, ill, and those with extensive
plaque burden. A primary patency rate of 79.2% at a mean
follow-up of 12.7 months was achieved in the absence of
stent fracture with a 12-cm mean stent length. The patients
as a group displayed a high mortality rate, as expected for
the type of patients enrolled. The relatively high number
of patients requiring reintervention suggests that frequent
and short-interval surveillance is mandatory for early diag-
nosis of potential issues related to the revascularization of
this arterial segment. Further investigation is necessary;
however, the results suggest that intervention in areas
with complex biomechanical forces, such as across the
knee joint, can be performed with acceptable results using
currently available interwoven wire nitinol devices.
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